SCHEMBL3054191

SCHEMBL3054191

CN(C)CCCNC(=O)CNC(=O)c1ccc(S(=O)(=O)Nc2ccccc2Oc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 7/20 0.62
CACNA1H O95180 6/20 0.62
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 2/20 0.45
LIMK2 P53671 1/20 0.45
PTGDR2 Q9Y5Y4 2/20 0.45
MCHR1 Q99705 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054424 0.91 CACNA1H (0.51) CACNA1BCACNA1HMEN1POLBKMT2A
SCHEMBL3054853 0.91 POLB (0.52) CACNA1BCACNA1HMEN1POLBKMT2A
SCHEMBL3050369 0.90 POLB (0.51) CACNA1BCACNA1HMEN1POLBKMT2A
SCHEMBL13835112 0.89 POLB (0.53) CACNA1BCACNA1HMEN1POLBKMT2A
SCHEMBL3056891 0.87 CACNA1H (0.47) CACNA1BCACNA1HMEN1KMT2ALIMK2
Hydrochloric Acid SCHEMBL3053753 0.86 POLB (0.51) CACNA1BCACNA1HMEN1POLBKMT2A
SCHEMBL3053482 0.86 PTGDR (0.46) CACNA1BCACNA1HKMT2APTGDR2
SCHEMBL3047254 0.85 CACNA1H (0.59) CACNA1BCACNA1HPOLBTDP1LIMK2
SCHEMBL3050672 0.83 CCR2 (0.53) MEN1POLBKMT2A
SCHEMBL3047854 0.82 PTGDR2 (0.57) CACNA1BCACNA1HMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2057116-B1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-02-13 EP claimed
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-29 US claimed
EP-2057116-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-05-13 EP claimed
WO-2008050167-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO claimed
EP-2057116-B1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-02-13 EP disclosed
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2013-01-31 US disclosed
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BEKE GYULA (HU) 2012-11-22 US disclosed
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295910-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 CACNA1B 1550/4885CACNA1H 1604/4885MEN1 2640/4885
US-20130029991-A1 New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists BDKRB1, BDKRB2, HRH4 CACNA1B 1486/4885CACNA1H 1596/4885MEN1 2895/4885
US-20100105686-A1 PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, HRH1 CACNA1B 1599/4885CACNA1H 1681/4885MEN1 2650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.